# InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte(TM) in early-stage cutaneous T-cell lymphoma, an 18-week study enrolling about 80 patients with top-line results expected in the second half of 2026, as the company strengthens European engagement ahead of potential commercialization.

 To view the full press release, visit https://ibn.fm/b9dsR

 About Soligenix

 Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behcet’s Disease.

 Our Public Health Solutions business segment includes development programs for RiVax(R), our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

 NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-soligenix-inc-nasdaq-sngx-expands-european-medical-advisory-board-to-advance-hybryte-phase-3-study/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/soligenix-expands-european-board-for-hybrytetm-ctcl-trial/2a3d27d7498b69b3793ff7f8a10c5bba) 


Pickup - [https://faqstaq.news/news](https://faqstaq.news/news/202509/239281-faq-soligenix-expands-european-medical-advisory-board-for-hybryte-phase-3-study-in-cutaneous-t-cell-lymphoma)

Pickup - [https://goinvest.com/ibn-faqstaq](https://goinvest.com/ibn-faqstaq/202509/239290-faq-soligenix-expands-european-medical-advisory-board-for-hybryte-phase-3-study)

Pickup - [https://burstable.news/news](https://burstable.news/news/202509/239338-soligenix-expands-european-medical-advisory-board-to-advance-hybryte-phase-3-study-for-cutaneous-t-cell-lymphoma)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202509/239346-soligenix-amplia-su-consejo-medico-europeo-para-avanzar-en-estudio-de-fase-3-de-hybryte-para-linfoma-cutaneo)

Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202509/239485-soligenix-erweitert-europaisches-medizinisches-beratungsgremium-fur-hybryte-phase-3-studie-bei-kutanem-t-zell-lymphom)

Pickup - [https://actueclair.com](https://actueclair.com/202509/239457-soligenix-elargit-son-conseil-consultatif-medical-europeen-pour-faire-avancer-l-etude-de-phase-3-d-hybryte-dans-le-lymphome-cutane)
 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/259/30/daveNlrg.webp)